Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets

Simply Wall St.03-12

Agilent Technologies (NYSE:A) has agreed to acquire Biocare Medical for $950 million. The deal is Agilent’s largest since 2019 and expands its pathology and immunohistochemistry portfolio. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618920521?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530","is_english":true,"pubTime":"2026-03-12 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618920521","market":"hk","top_or_hot":-1,"title":"Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets","media":"Simply Wall St.","content":"<div>\n<p>Agilent Technologies (NYSE:A) has agreed to acquire Biocare Medical for $950 million. The deal is Agilent’s largest since 2019 and expands its pathology and immunohistochemistry portfolio. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilents-biocare-deal-reshapes-pathology-presence-as-shares\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent’s Biocare Deal Reshapes Pathology Presence As Shares Lag Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 01:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilents-biocare-deal-reshapes-pathology-presence-as-shares><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agilent Technologies (NYSE:A) has agreed to acquire Biocare Medical for $950 million. The deal is Agilent’s largest since 2019 and expands its pathology and immunohistochemistry portfolio. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilents-biocare-deal-reshapes-pathology-presence-as-shares\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1165135440.EUR","symbol_name":"BNP Paribas Aqua Classic Cap EUR","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilents-biocare-deal-reshapes-pathology-presence-as-shares","article_id":"2618920521","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/154924-main-header/1756254020530"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilents-biocare-deal-reshapes-pathology-presence-as-shares","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618920521","pubTimestamp":1773249627,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agilent Technologies (NYSE:A) has agreed to acquire Biocare Medical for $950 million.\nThe deal is Agilent’s largest since 2019 and expands its pathology and immunohistochemistry portfolio.\nThe transaction is expected to affect revenue, margins, and earnings per share within about a year of closing.\n\nAgilent Technologies, trading at $115.43, is moving to deepen its position in life sciences and diagnostics with the planned purchase of Biocare Medical. The company’s share performance has been...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4567":"ESG概念","BK4588":"碎股","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","BK4585":"ETF&股票定投概念","LU2041044095.USD":"Blackrock Circular Economy A2 USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU1543694498.USD":"法巴水资源基金RH MD Dis","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","BK4121":"生命科学工具和服务","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","A":"安捷伦科技"},"translate_title":"由于股价落后于目标，安捷伦的Biocare交易重塑了病理学领域","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1.5},"content_text":"Agilent Technologies (NYSE:A) has agreed to acquire Biocare Medical for $950 million. The deal is Agilent’s largest since 2019 and expands its pathology and immunohistochemistry portfolio. The transaction is expected to affect revenue, margins, and earnings per share within about a year of closing.  Agilent Technologies, trading at $115.43, is moving to deepen its position in life sciences and diagnostics with the planned purchase of Biocare Medical. The company’s share performance has been under pressure, with the stock down 10.9% over the past month and 16.3% year to date. Over a 3 year and 5 year period, the stock has also declined 14.7% and 2.9% respectively. This gives the move added significance for investors watching NYSE:A. Management is framing the Biocare deal as a way to build out Agilent’s footprint in clinical and research pathology labs and complement the existing diagnostics portfolio. As integration progresses, investors may watch how quickly the combined business affects revenue mix, margin profile, and earnings per share, along with any updates on the timing and terms of closing. Stay updated on the most important news stories for Agilent Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Agilent Technologies. NYSE:A Earnings & Revenue Growth as at Mar 2026 We've flagged 0 risks for Agilent Technologies. See which could impact your investment. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$115.43 versus a consensus target of US$163.29, the share price is about 28% below where analysts currently sit. ⚖️ Simply Wall St Valuation: Shares are described as trading close to estimated fair value, so this deal news comes on top of a roughly balanced valuation view. ❌ Recent Momentum: The stock has seen a 10.9% decline over the last 30 days, which may signal some caution in the near term.  There's only one way to know the right time to buy, sell or hold Agilent Technologies. Head to Simply Wall St's\ncompany report for the latest analysis of Agilent Technologies's Fair Value. Key Considerations  📊 The Biocare acquisition adds scale in pathology and immunohistochemistry, which could reshape how much of Agilent's business comes from diagnostics over time. 📊 Watch any commentary on integration costs, updated margin guidance and how quickly management expects the US$950m outlay to influence earnings per share. ⚠️ Execution risk around integrating Biocare and delivering on revenue and margin expectations is a key factor to monitor as the deal moves toward closing.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Agilent Technologies analysis. Alternatively, you can check out the\ncommunity page for Agilent Technologies to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618920521","isCrawlerRequest":true}